151 related articles for article (PubMed ID: 36934225)
1. DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells.
Li W; Liu S; Wang C; Cui L; Zhao X; Liu W; Zhang R; Li Z
BMC Cancer; 2023 Mar; 23(1):255. PubMed ID: 36934225
[TBL] [Abstract][Full Text] [Related]
2. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.
den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
Leukemia; 1998 Jun; 12(6):912-20. PubMed ID: 9639420
[TBL] [Abstract][Full Text] [Related]
3. Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia.
Mei Y; Gao C; Wang K; Cui L; Li W; Zhao X; Liu F; Wu M; Deng G; Ding W; Jia H; Li Z
Cancer Sci; 2014 Apr; 105(4):463-72. PubMed ID: 24720529
[TBL] [Abstract][Full Text] [Related]
4. Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia.
Den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
Leukemia; 1999 Dec; 13(12):2023-30. PubMed ID: 10602424
[TBL] [Abstract][Full Text] [Related]
5. Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy.
Watanabe A; Inukai T; Kagami K; Abe M; Takagi M; Fukushima T; Fukushima H; Nanmoku T; Terui K; Ito T; Toki T; Ito E; Fujimura J; Goto H; Endo M; Look T; Kamps M; Minegishi M; Takita J; Inaba T; Takahashi H; Ohara A; Harama D; Shinohara T; Somazu S; Oshiro H; Akahane K; Goi K; Sugita K
Cancer Med; 2019 Sep; 8(11):5274-5288. PubMed ID: 31305009
[TBL] [Abstract][Full Text] [Related]
6. DNMT3A mutations and prognostic significance in childhood acute lymphoblastic leukemia.
Li W; Gao C; Cui L; Liu S; Zhao X; Zhang R; Wu M; Zheng H; Deng G; Li Z; Zhang Q
Leuk Lymphoma; 2015 Apr; 56(4):1066-71. PubMed ID: 25242092
[TBL] [Abstract][Full Text] [Related]
7. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia.
Pieters R; Kaspers GJ; van Wering ER; Huismans DR; Loonen AH; Hählen K; Veerman AJ
Leukemia; 1993 Mar; 7(3):392-7. PubMed ID: 8445945
[TBL] [Abstract][Full Text] [Related]
8. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Signal; 2023 May; 105():110626. PubMed ID: 36758683
[TBL] [Abstract][Full Text] [Related]
9. [Expression of survivin and its location in bone marrow cells of childhood acute leukemia: relationship to therapeutic efficacy].
Hou Y; Hu Q; Liu AG; Zhang LQ; Liu SY
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Apr; 8(2):101-4. PubMed ID: 16613699
[TBL] [Abstract][Full Text] [Related]
10. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Insulin-mediated Regulation of AKT Signaling in Childhood Acute Lymphoblastic Leukemia.
Wang J; Xue HM; Chen YR; Xu HG; Lin SF; Tang XK; Chen C
J Pediatr Hematol Oncol; 2019 Mar; 41(2):96-104. PubMed ID: 30688831
[TBL] [Abstract][Full Text] [Related]
12. Resistance of bcr-abl-positive acute lymphoblastic leukemia to daunorubicin is not mediated by mdr1 gene expression.
Gupta M; Kumar A; Dabadghao S
Am J Hematol; 2002 Nov; 71(3):172-6. PubMed ID: 12410571
[TBL] [Abstract][Full Text] [Related]
13. The prognostic potential of coilin in association with p27 expression in pediatric acute lymphoblastic leukemia for disease relapse.
Yue ZX; Gao RQ; Gao C; Liu SG; Zhao XX; Xing TY; Niu J; Li ZG; Zheng HY; Ding W
Cancer Cell Int; 2018; 18():106. PubMed ID: 30065619
[TBL] [Abstract][Full Text] [Related]
14. Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells.
Gao C; Liu SG; Lu WT; Yue ZX; Zhao XX; Xing TY; Chen ZP; Zheng HY; Li ZG
Mol Med Rep; 2020 Oct; 22(4):2905-2915. PubMed ID: 32945392
[TBL] [Abstract][Full Text] [Related]
15. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
16. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia.
Klumper E; Giaccone G; Pieters R; Broekema G; van Ark-Otte J; van Wering ER; Kaspers GJ; Veerman AJ
Leukemia; 1995 Oct; 9(10):1653-60. PubMed ID: 7564505
[TBL] [Abstract][Full Text] [Related]
18. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.
Kaspers GL; Veerman AJ; Pieters R; van Zantwijk I; Klumper E; Hählen K; de Waal FC; van Wering ER
Leukemia; 1994 Jan; 8(1):24-9. PubMed ID: 8289494
[TBL] [Abstract][Full Text] [Related]
20. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.
Rammeloo LA; Postma A; Sobotka-Plojhar MA; Bink-Boelkens MT; Berg A; Veerman AJ; Kamps WA
Med Pediatr Oncol; 2000 Jul; 35(1):13-9. PubMed ID: 10881002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
